Clinical, microbiological and pharmacokinetic studies on ofloxacin in acute purulent exacerbations of chronic respiratory disease.
Thirty hospital patients with acute purulent exacerbations of chronic respiratory disease were treated with 400 mg ofloxacin by mouth either once or twice daily for ten days. Studies on concomitantly administered theophylline showed no significant accumulation. Most sputum cultures no longer yielded pathogens at the end-of-treatment, but some Pseudomonas aeruginosa strains persisted. Clinical results were usually excellent at the end of treatment (26/30 patients) and excellent or good a week later (24/30), although they were better in the patients receiving once daily dosage. One patient developed a maculopapular drug rash which disappeared when ofloxacin was discontinued.
Maesen
F P
FP
Davies
B I
BI
Baur
C
C
Sumajow
C A
CA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000378:metabolism / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013183:Sputum / Q000032:analysis / Q000382:microbiology; D013806:Theophylline / Q000378:metabolism / Q000627:therapeutic use
D010078:Oxazines; D015242:Ofloxacin; D013806:Theophylline